# Namur Invest

> Namur Invest is a VC fund in Namur backing Health Care, Medical Device and Auctions. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Namur, Belgium
- Total investments: 8
- Last investment: Mar 2026
- Lead investor: 25%
- Last updated: Aug 2026
- Website: http://www.namurinvest.be

Namur Invest is a VC fund in Namur focused on Health Care and Medical Device. Namur Invest Group provides companies with financing solutions in various forms adapted to their needs, to strengthen their financial.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $658k–$18M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 38% |
| Medical Device | 2 | 25% |
| Auctions | 1 | 13% |
| Software | 1 | 13% |
| Wellness | 1 | 13% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Funding Round | 2 | 25% |
| Seed | 1 | 13% |
| Grant | 1 | 13% |
| Post-IPO Debt | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 4 | 50% |
| United States | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| VolitionRx | Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease ispresent.As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide. | $2.3M | Grant | Mar 31, 2026 |  |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $29.2M |  | Sep 25, 2025 |  |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $18M | Series A | Mar 09, 2023 |  |
| VolitionRx | Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease ispresent.As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide. | $1.5M | Post-IPO Debt | Aug 03, 2022 |  |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $7.3M | Seed | Dec 15, 2021 |  |
| Invineo | Invineo design and development of a "smart machine" for catering and hospitality professionals. | $2.7M |  | Apr 19, 2018 |  |
| iSTAR Medical | iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium.By 2012, iSTAR received ISO 13485 and ISO 9001 Quality SystemsCertifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant. | $4.4M | Series A | Nov 21, 2013 |  |
| Auctelia | Auctelia offers industrial companies a simple way to manage efficiently their assets throughout their life cycle.Auctelia currently allows companies and intermediaries to sell and buy industrial assets through an effective online auction process. More than 30,000 members from 30 countries are logged in as buyers and Auctelia already managedsales of over EUR 10 of millions worth in assets. | $658K | Series A | Dec 01, 2011 |  |

8 of 8 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 3 deals together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 2 deals together
- [Invest Mons Borinage Centre](https://shizune.co/investors/profile/invest-mons-borinage-centre) — VC Fund, 2 deals together
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 2 deals together
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 2 deals together
- [Vives Louvain Technology Fund](https://shizune.co/investors/profile/vives-fund) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All Investors in Belgium](https://shizune.co/investors/investors-belgium)
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [Medical Device Investors in Belgium](https://shizune.co/investors/medical-device-investors-belgium)
- [Medical Device VC Funds in Belgium](https://shizune.co/investors/medical-device-vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)

## FAQ

### What does Namur Invest invest in?

Namur Invest invests primarily in Health Care, Medical Device and Auctions startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Namur Invest's check size?

Namur Invest typically joins rounds of $658k–$18M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Namur Invest participates in.

### When did Namur Invest last invest?

The most recent investment recorded for Namur Invest closed in Mar 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co